58 results on '"Medioni, J"'
Search Results
2. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
3. Prise en charge de la douleur neuropathique induite par la chirurgie : revue de la littérature par un groupe d’experts spécialisés en gestion de la douleur, anesthésie et chirurgie
4. Management of neuropathic pain induced by surgery: Review of the literature by a group of experts specialized in pain management, anesthesia and surgery
5. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
6. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
7. Terapia antiestrogénica en los cánceres de mama
8. 36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
9. Évaluation radiologique de la réponse au traitement : application aux cancers du rein métastatiques sous traitement anti-angiogénique
10. Radiological evaluation of response to treatment: Application to metastatic renal cancers receiving anti-angiogenic treatment
11. 346MO Trastuzumab deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies
12. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
13. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
14. Inhibiteurs de l’angiogenèse : revues de l’apport thérapeutique du sorafenib, du sunitinib et du bevacizumab dans le cancer du rein métastatique
15. Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
16. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
17. Treatment options in renal cell carcinoma: past, present and future
18. Wide metastatic spreading in infiltrating lobular carcinoma of the breast
19. 544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study
20. POSB397 Benefits of Homeopathic Complementary Treatment in Breast Cancer Patients: A Retrospective Cohort Study Based on the French Nationwide Healthcare Database (SNDS)
21. SIOG2021-0014 - Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort
22. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
23. 387TiP - Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial
24. 1175P - Prognostic value of response according to tumour growth rate in a phase I trial on vaccine therapy
25. 972P - Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)
26. 415PD - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors
27. 973P - A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC)
28. 947P - Circulating tumor cells as prognostic marker in ovarian carcinoma: Results from the ANTHALYA study
29. Clinical evaluation of early predictors of renal transplantation results
30. 853TiP - Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases
31. 2772 Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting
32. 1582 Longitudinal study on the impact of patient-reported fatigue on survival in metastatic cancer patients treated with chemotherapy
33. 1568 Deleterious joint effect of fatigue and anemia in cancer patients treated with chemotherapy
34. 1503 Impact of pain on survival in metastatic cancer patients treated with chemotherapy: A prospective longitudinal study of patient-reported severity
35. 1510P - Anemia As an Explanatory Factor for Fatigue in Patients Treated with Chemotherapy
36. 866P - Impact of Platinum Agent [Cisplatin (Cis) or Carboplatin (Ca)] in First-Line Chemotherapy (Ct) on Overall Survival in Metastatic Urothelial Carcinoma (Muc) Patients (Pts): a Retrospective Study
37. 292P - Radiological-Histological Size Correlation in Triple-Negative Breast Cancer (Tnbc)
38. 1545O - Fatigue (F) and Anemia Scores for Overall Survival (OS) Prognosis
39. 966O - Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)
40. 852P - Predictive Value of Time to Best Response for Efficacy MTOR Inhibitors (MTORI) in Metastatic Renal Cell Carcinoma (MRCC) Patients (PTS)
41. 845P - Biological Toxicity can be a Surrogate Marker of Efficacy in Patients (PTS) Treated with MTOR Inhibitors (MTORI) for MRCC
42. 258P - Prognostic Factors in Early-Stage Triple Negative Breast Cancer (TNBC): The Limits Of Clinical and Pathological Features
43. Psychotropic prescription in non-psychiatric hospital settings
44. 430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)
45. RI-WS-19 Evaluation prospective du traitement de metastases osseuses pelviennes douloureuses avec embolisation radio-frequence et cimentoplastie
46. ONCO-WS-15 Optimisation du seuil de variation recist dans l’evaluation apres traitement antiangiogenique du cancer renal metastatique
47. Evaluation prospective du traitement de metastases osseuses pelviennes douloureuses avec embolisation radio-frequence et cimentoplastie
48. Optimisation du seuil de variation recist dans l’evaluation apres traitement antiangiogenique du cancer renal metastatique
49. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
50. 7030 Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.